At International Investigative Dermatology Meeting (IID) in Orlando, Florida
Glenmark Pharmaceuticals announced data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID) in Orlando, Florida. The exploratory Phase 2a study was conducted to investigate the safety of GBR 830, evaluate its effects on AD biomarkers, and generate the first clinical evidence of its biological activity. Patients were randomized to receive two doses of GBR 830 or placebo, and were assessed for response at Day 29 and Day 71.New data from the study demonstrated that subsequent to treatment with GBR 830, epidermal hyperplasia, proliferation, and mRNA biomarkers for disease activity were reduced, indicating a possible effect on both the acute and chronic stages of AD.
The GBR 830 Phase 2a study has been completed. Enrollment for a Phase 2b study in AD is expected to begin in June 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
